NeoChord Names David Chung President And CEO - Quick Facts

(RTTNews) - NeoChord, a medical device company focused on minimally invasive mitral valve repair, announced that it has appointed David Chung as President and Chief Executive Officer, effective immediately, replacing John Seaberg, who resigned.

David Chung has 20+ years of hospital-focused, global medical device and pharmaceutical senior leadership. His cardiovascular experience includes 15 years with Edwards Lifesciences, culminating in his role as Global Vice President of Commercial Operations for the heart valve therapy franchise. Chung left Edwards to lead Mitralis, an early-stage, transcatheter mitral valve repair company, as President and CEO. Most recently, he served as Chief Commercial Officer at AcelRx Pharmaceuticals Inc.(ACRX), a specialty pharmaceutical company. Prior to AcelRx, Chung was Chief Commercial Officer for Conceptus (Bayer). He began his career at Pfizer in a variety of sales roles.

NeoChord also announced that Michael Fulton, a NeoChord director, has been elected as Chairman of the Board. Michael Fulton, a Managing Director at Hopen Life Science Ventures, has over 20 years of experience in the life sciences space. Prior to Hopen, Fulton was a successful entrepreneur in the medical device and health services sectors.